

Cover Story
By Matthew Bin Han Ong
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - Cancer Research Institute announces 2025 recipients of cancer immunotherapy awards
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- USPSTF doesn’t lean right or left—it’s about data, not politics